RaQualia Pharma, Inc.

RaQualia Pharma, Inc.

RaQualia Pharma, Inc.

Overview
Date Founded

2008

Headquarters

Meieki Southside Square, 8/F,1-21-19 Meikei Minami,Nakamura-Ku,Nagoya, Aichi 450-0003

Type of Company

Public

Employees (Worldwide)

68

Industries

Pharmaceuticals

Company Description

RaQualia Pharma, Inc. engages in a research and development of pharmaceuticals. Its medicines focus on pain, gastrointestinal, auto-immune diseases, inflammation, cancer, and Alzheimer's. Its products include Anidulafungin, Dalbavancin, Ziprasidone, 5-HT4 Partial Agonist, and 5-HT2B Antagonist. The company was founded on February 19, 2008 and is headquartered in Nagoya, Japan.

Website

http://www.raqualia.co.jp

In The News
Business Wire
August 13, 2020
Global Postoperative Ileus Pipeline Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Updates, Status and Outlook - ResearchAndMarkets.com
Business Wire
February 3, 2020
Global Pipeline Review for Functional (Non Ulcer) Dyspepsia - H1 2020 - ResearchAndMarkets.com
Business Wire
May 23, 2019
Functional (Non Ulcer) Dyspepsia Pipeline Review, H1 2019 Report Featuring Daewoong Pharmaceutical, RaQualia Pharma, & Zeria Pharmaceutical - ResearchAndMarkets.com
PR Newswire
November 27, 2018
The global GERD drug and devices market has been predicted to grow at a CAGR of 1.12% between 2019 and 2027
Business Wire
September 28, 2018
Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2018 Featuring Daewoong Pharmaceutical, RaQualia Pharma & Zeria Pharmaceutical - ResearchAndMarkets.com

Reveal deeper insights into your organization's relationships
with RelSci Contact Aggregator.

Empower Your Business Applications with Industry-Leading
Relationship Data from the RelSci API.

Get Contact Information on the
World's Most Influential Decision Makers.

Discover the Power of Your Network with
RelSci Premium Products.
Executives & Employees
See More
Naoki Tani

Representative Director

Kiichiro Kawada

Chief Financial Officer, Director & Managing Executive Director

Shuzo Watanabe

Executive Officer & Head-Drug Discovery Research

Yasuhiro Takamatsu

Director, Head-Personnel & Legal Affairs

Kaoru Shimada

Vice President

Board of Directors
Naoki Tani

Representative Director at RaQualia Pharma, Inc.

Shuzo Watanabe

Executive Officer & Head-Drug Discovery Research at RaQualia Pharma, Inc.

Shinnosuke Maki

Independent Outside Director at PCI Holdings, Inc.

Hisaji Agata

Auditor at TMRC Co. Ltd.

Gakuji Nomoto

Independent Outside Director at RaQualia Pharma, Inc.

Michihiro Tsuchiya

Director at Sumitomo Electric U.S.A. Holdings, Inc.

Kiichiro Kawada

Chief Financial Officer, Director & Managing Executive Director at RaQualia Pharma, Inc.

Trending People
US Department of Housing & Urban Development (DC)
Biden has big plans for homelessness - but will it help Seattle? - The Seattle Times
European Union
Bangladeshi drugmaker acquiring country's Sanofi subsidiary - Associated Press
Bank of England
Could sustainable diets be the next lockdown casualty? - The Independent UK
Eli Lilly & Company
Drug Prevents Coronavirus Infection in Nursing Homes, Maker Claims - The New York Times
World Health Organization
French victims of child abuse speak out in new #MeToo wave - The Independent UK
Trending Organizations
US Department of Housing & Urban Development (DC)
Biden has big plans for homelessness - but will it help Seattle? - The Seattle Times
European Union
Bangladeshi drugmaker acquiring country's Sanofi subsidiary - Associated Press
Bank of England
Could sustainable diets be the next lockdown casualty? - The Independent UK
Eli Lilly & Company
Drug Prevents Coronavirus Infection in Nursing Homes, Maker Claims - The New York Times
World Health Organization
French victims of child abuse speak out in new #MeToo wave - The Independent UK
Paths to RaQualia Pharma, Inc.
Potential Connections via
Relationship Science
You
RaQualia Pharma, Inc.
Recent Transactions
Details Hidden

RaQualia Pharma, Inc. purchases TMRC Co. Ltd.

Details Hidden

RaQualia Pharma, Inc. issued JPY Ordinary Shares

Transaction Advisors
Underwriter
Ace Securities Co., Ltd. (Broker)

Advised onRaQualia Pharma, Inc. issued JPY Ordinary Shares

Underwriter
Aizawa Securities Co., Ltd. (Broker)

Advised onRaQualia Pharma, Inc. issued JPY Ordinary Shares

Underwriter
Daiwa Securities Capital Markets Co., Ltd.

Advised onRaQualia Pharma, Inc. issued JPY Ordinary Shares
Clients
CJ Corp.

CJ Corp. engages in managing investments. The company through its subsidiaries operates in the following businesses: Food and Food services, Retail and Logistics, Entertainment and Media, Infrastructure, and Life Science. The company was founded on August 1, 1953 and is headquartered in Seoul, South Korea.

Elanco Animal Health, Inc.

Elanco Animal Health, Inc. engages in the innovation, development, manufacture and market products for companion and food animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. The Companion Animal Disease Prevention category engages in the broadest parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. The Companion Animal Therapeutics category provides the details of broad pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. The Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics, serves the growing demand for protein and includes innovative products in poultry and aquaculture production, where demand for animal health products is outpacing overall industry growth. It also focuses on developing functional nutritional health products that promote food animal health, including enzymes, probiotics and prebiotics. The Food Animal Ruminants & Swine category develops animal food products used in ruminant and swine production. The company was founded on May 3, 2018 and is headquartered in Greenfield, IN.

Kolmar Korea Co., Ltd.

Kolmar Korea Co., Ltd. engages in the original design manufacturing and original equipment manufacturing of cosmetics and pharmaceuticals. It operates through the following business areas: Cosmetics, Pharmaceuticals and Health Functional Foods. The Cosmetics business offers skin care, make up, perfume, quasi drugs, hair care and body care. The Pharmaceuticals business provides specialized medicines, general medicines, bio-equivalence medicine, contract process and quasi drugs. The Health Functional Foods business offers functional health foods, new material development, special foods and other individual sectors. The company was founded on May 15, 1990 and is headquartered in Sejong, South Korea.
Key Stats and Financials As of 2019
Market Capitalization
$210M
Total Enterprise Value
$232M
Earnings Per Share
$0
EBITDAMargin
7.29%
Enterprise Value / Sales
14.94x
Enterprise Value EBITDAOperating
205.06x
TEVNet Income
4,763.12x
Debt TEV
0x
Three Year Compounded Annual Growth Rate Of Revenue
34.16%
Revenue
$15.5M
Net Profit
$48.7K
EBITDA
$1.13M
Total Debt
$21.9K
Total Equity
$42.1M
Investments
Details Hidden
Aratana Therapeutics, Inc.

Aratana Therapeutics, Inc. engages in the development and commercialization of pet therapeutics. Its portfolio includes NOCITA, ENTYCE, and GALLIPRANT. NOCITA (bupivacaine liposome injectable suspension) acts as a local post-operative analgesia for cranial cruciate ligament surgery in dogs, and as a peripheral nerve block to provide regional post-operative analgesia following onychectomy in cats. ENTYCE(capromorelin oral solution) is intended for appetite stimulation in dogs. GALLIPRANT (grapiprant tablets) is for the control of pain and inflammation associated with osteoarthritis in dogs. The company was founded by Linda Rhodes and Steven St. Peter on December 1, 2010 and is headquartered in Leawood, KS.

Investors
Details Hidden
Naoki Tani

Representative Director at RaQualia Pharma, Inc.

Details Hidden
The University of Tokyo Edge Capital Co. Ltd.

UTEC is an active manager which invests in Japanese startup companies. The firm invests in companies in the technology sectors. UTECinvests as a minority shareholder requiring a seat in the board of directors. The firm particularly targets seed and early stage companies.

Suppliers
Pfizer, Inc. Medical Support Services | New York, NY

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Stay informed and up-to-date on your network with RelSci news and business alerting service. Nurture your network and further your business goals with smart intelligence on the people and companies that matter most to you.

Browse in-depth profiles on 12 million influential people and organizations. Find RelSci relationships, employment history, board memberships, donations, awards, and more.

Explore notable alumni from top universities and organizations. Expand your fundraising pool and make warm introductions to potential new business connections.

Harness the power of your relationships with RelSci Pro, the powerful platform for identifying relationship-driven business opportunities and connections that can propel your career forward.

Stay informed and up-to-date on your network with RelSci news and business alerting service. Nurture your network and further your business goals with smart intelligence on the people and companies that matter most to you.

Browse in-depth profiles on 12 million influential people and organizations. Find RelSci relationships, employment history, board memberships, donations, awards, and more.

Explore notable alumni from top universities and organizations. Expand your fundraising pool and make warm introductions to potential new business connections.

Harness the power of your relationships with RelSci Pro, the powerful platform for identifying relationship-driven business opportunities and connections that can propel your career forward.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by RaQualia Pharma, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of RaQualia Pharma, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and RaQualia Pharma, Inc..